36 research outputs found
Interventions to improve the experience of caring for people with severe mental illness: systematic review and meta-analysis
Background
Informal caregiving is an integral part of the care of people with severe mental illness, but the support needs of those providing such care are not often met.
Aims
To determine whether interventions provided to people caring for those with severe mental illness improve the experience of caring and reduce caregiver burden.
Method
We conducted a systematic review and meta-analyses of randomised controlled trials (RCTs) of interventions delivered by health and social care services to informal carers (i.e. family or friends who provide support to someone with severe mental illness).
Results
Twenty-one RCTs with 1589 carers were included in the review. There was evidence suggesting that the carers’ experience of care was improved at the end of the intervention by psychoeducation (standardised mean difference –1.03, 95% CI –1.69 to –0.36) and support groups (SMD = –1.16, 95% CI –1.96 to –0.36). Psychoeducation had a benefit on psychological distress more than 6 months later (SMD = –1.79, 95% CI –3.01 to –0.56) but not immediately post-intervention. Support interventions had a beneficial effect on psychological distress at the end of the intervention (SMD = –0.99, 95% CI –1.48 to –0.49) as did problem-solving bibliotherapy (SMD = –1.57, 95% CI –1.79 to –1.35); these effects were maintained at follow-up. The quality of the evidence was mainly low and very low. Evidence for combining these interventions and for self-help and self-management was inconclusive.
Conclusions
Carer-focused interventions appear to improve the experience of caring and quality of life and reduce psychological distress of those caring for people with severe mental illness, and these benefits may be gained in first-episode psychosis. Interventions for carers should be considered as part of integrated services for people with severe mental health problems
Self-management interventions for people with severe mental illness: a systematic review and meta-analysis
BACKGROUND:
Self-management is intended to empower individuals in their recovery
by providing the skills and confidence they need to take active steps to recognise and
manage their own health problems. Evidence supports such interventions in a range
of long-term physical health conditions, but a recent systematic synthesis is not
available for people with severe mental health problems.
// AIMS:
To evaluate the effectiveness of self-management interventions for adults with
severe mental illness (SMI).
// METHODS:
A systematic review of randomised controlled trials was conducted. A
meta-analysis of symptomatic, relapse, recovery, functioning and quality of life
outcomes was conducted using Revman.
// RESULTS:
Thirty-seven trials were included with 5790 participants. From the metaanalysis, self-management interventions conferred benefits in terms of reducing
symptoms and length of admission, and improving functioning and quality of life
both at the end of treatment and at follow up. Overall the effect size was small to
medium. The evidence for self-management interventions on readmissions was
mixed. However, self-management did have a significant effect compared to control
on subjective measures of recovery such as hope and empowerment at follow up, and
self-rated recovery and self-efficacy at both time points.
// CONCLUSION:
There is evidence that the provision of self-management interventions
alongside standard care improves outcomes for people with severe mental illness.
Self-management interventions should form part of the standard package of care
provided to people with severe mental illness and should be prioritised in guidelines:
research on best methods of implementing such interventions in routine practice is
needed
Fifteen-month follow up of an assertive community treatment program for chronic patients with mental illness
A systematic review of maternal antidepressant use in pregnancy and short- and long-term offspring's outcomes
The relative safety of antidepressants during pregnancy has received substantial attention, but most syntheses fail to account for mental illness effects. We aimed to evaluate the literature comparing low birth weight (LBW) and neurodevelopmental and neurobehavioural outcomes for children whose mothers took antidepressants in pregnancy compared to those whose mothers had common mental disorders, or symptoms, but who did not take antidepressants during pregnancy. A systematic review was conducted searching PubMed, MEDLINE, PsycINFO and Embase in January 2015. A modified version of the Newcastle Ottawa Scale was used to assess study quality. Eleven cohort studies were included: four reporting a LBW outcome (all with higher risk of bias) and seven reporting a neurodevelopmental outcome (five with higher risk of bias). We found only limited evidence of gestational age-adjusted LBW in exposed children in two studies which had a higher risk of bias and did not control for depressive symptom severity. Only five (7.5%) neurodevelopmental outcomes and one (12.5%) neurobehavioural outcome showed evidence of a statistically significant effect, three out of four were from studies with a higher risk of bias. There is little robust evidence indicating a detrimental effect of antidepressant use during pregnancy on LBW and neurodevelopmental and neurobehavioural outcomes. More rigorous study designs are needed
Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review
Implementing the most suitable treatment strategies and making appropriate clinical decisions about individuals with a first episode of psychosis (FEP) is a complex and crucial task, with relevant impact in illness outcome. Treatment approaches in the early stages should go beyond choosing the right antipsychotic drug and should also address tractable factors influencing the risk of relapse. Effectiveness and likely metabolic and endocrine disturbances differ among second-generation antipsychotics (SGAs) and should guide the choice of the first-line treatment. Clinicians should be aware of the high risk of cardiovascular morbidity and mortality in schizophrenia patients, and therefore monitoring weight and metabolic changes across time is mandatory. Behavioral and counseling interventions might be partly effective in reducing weight gain and metabolic disturbances. Ziprasidone and aripiprazole have been described to be least commonly associated with weight gain or metabolic changes. In addition, some of the SGAs (risperidone, amisulpride, and paliperidone) have been associated with a significant increase of plasma prolactin levels. Overall, in cases of FEP, there should be a clear recommendation of using lower doses of the antipsychotic medication. If no or minimal clinical improvement is found after 2 weeks of treatment, such patients may benefit from a change or augmentation of treatment. Clinicians should provide accurate information to patients and relatives about the high risk of relapse if antipsychotics are discontinued, even if patients have been symptom free and functionally recovered on antipsychotic treatment for a lengthy period of time.This review was carried out at the Hospital Marque´s de Valdecilla, University of Cantabria, Santander, Spain, with the following Grant support: Instituto de Salud Carlos III PI020499, PI050427, PI060507, Plan Nacional de Drugs Research Grant 2005-Orden sco/3246/2004, SENY Fundacio´ Research Grant CI 2005-0308007, Fundacio´n Marque´s de Valdecilla API07/011 and CIBERSAM